For the quarter ending 2025-09-30, RLMD made $10,644,634 in revenue. -$10,091,496 in net income. Net profit margin of -94.80%.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 4,036,267 | 2,819,377 | ||
| General and administrative | 6,291,079 | 7,401,929 | ||
| Total operating expenses | 10,327,346 | 10,221,306 | ||
| Loss from operations | -10,327,346 | -10,221,306 | ||
| Interest/investment income, net | 247,013 | 321,458 | ||
| Realized (loss) gain on short-term investments | -81,438 | 47,203 | ||
| Unrealized gain on short-term investments | 70,275 | -13,797 | ||
| Total other (expense) income net | 235,850 | 354,864 | ||
| Net loss | -10,091,496 | -9,866,442 | ||
| Loss per common share basic (in dollars per share) | -0.3 | -0.3 | ||
| Loss per common share diluted (in dollars per share) | -0.3 | -0.3 | ||
| Weighted average number of common shares outstanding basic (in shares) | 33,191,622 | 33,191,622 | ||
| Weighted average number of common shares outstanding diluted (in shares) | 33,191,622 | 33,191,622 | ||
RELMADA THERAPEUTICS, INC. (RLMD)
RELMADA THERAPEUTICS, INC. (RLMD)